The B Group, Inc. is an exempt reporting adviser based in Dallas, TX that reports managing 1 hedge fund on Form ADV. Its private funds, of all types, hold $115.6 million in gross assets. Its disclosed U.S. stock holdings returned an estimated -10.9% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +144.3% from Q1 2025 to Q2 2026, compared with +27.4% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- —Form ADV Item 5.F
- Gross assets of private funds
- $115.6 millionAll private fund types, Form ADV
- Hedge funds managed
- 11 private funds in total
- Employees
- —Form ADV Item 5.A
- Registration
- Exempt reporting adviserCRD 310357
- Latest Form ADV
- 03/03/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +18.3% | +14.8% |
| Q1 2026 | -24.6% | -4.6% |
| Q4 2025 | +20.5% | +2.4% |
| Q3 2025 | +1.2% | +7.8% |
| Q2 2025 | +7.8% | +10.4% |
| Q1 2025 | +108.5% | -4.5% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Largest disclosed holdings
- Adma Biologics Inc$27.3 million
- Palisade Bio Inc$23.9 million
- NRX Pharmaceuticals Inc$16.7 million
- Sensei Biotherapeutics Inc$15.3 million
- Taysha Gene Therapies Inc$12.3 million
- Praxis Precision Medicines I$11.1 million
- Cellectis S A$9.8 million
- Zai Lab LTD$8.6 million
- Structure Therapeutics Inc$7.5 million
- Oruka Therapeutics Inc$7.1 million
As of 2026-06-30, from 13F filing by B Group, Inc..
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. HedgeMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures